Last reviewed · How we verify
telbivudine or lamivudine
Telbivudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of viral DNA.
Telbivudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of viral DNA. Used for Chronic hepatitis B, Hepatitis B virus infection.
At a glance
| Generic name | telbivudine or lamivudine |
|---|---|
| Sponsor | Novartis |
| Drug class | Nucleoside reverse transcriptase inhibitor |
| Target | Hepatitis B virus DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
They do this by incorporating themselves into the viral DNA and causing chain termination during viral replication. This mechanism is specific to the treatment of viral infections such as hepatitis B.
Approved indications
- Chronic hepatitis B
- Hepatitis B virus infection
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (NA)
- Extension Study of Carvedilol RCT Study (NA)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B (PHASE2)
- Renoprotective Effects of Telbivudine in Chronic Hepatitis B (PHASE4)
- A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy
- An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- telbivudine or lamivudine CI brief — competitive landscape report
- telbivudine or lamivudine updates RSS · CI watch RSS
- Novartis portfolio CI